Free tool
FAERS Monitor: Janumet Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202270 or its brand name (Janumet Xr, Metformin Hydrochloride, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.
Reports
21,623
Serious
14,062
65% of reports
Hospitalization
7,059
Death reported
2,125
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,511
- diarrhoea1,398
- nausea1,110
- drug ineffective1,006
- fatigue902
- acute kidney injury838
- vomiting781
- weight decreased718
- dizziness639
- pancreatitis626
- dyspnoea623
- no adverse event623
- inappropriate schedule of drug administration617
- product dose omission issue614
- death606
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 39 |
| 2008 | 131 |
| 2009 | 254 |
| 2010 | 384 |
| 2011 | 539 |
| 2012 | 929 |
| 2013 | 1,368 |
| 2014 | 1,814 |
| 2015 | 2,375 |
| 2016 | 2,094 |
| 2017 | 1,659 |
| 2018 | 1,792 |
| 2019 | 1,645 |
| 2020 | 1,564 |
| 2021 | 1,323 |
| 2022 | 1,058 |
| 2023 | 926 |
| 2024 | 752 |
| 2025 | 598 |
| 2026 | 379 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,536 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancreatitisSignal | 626 | 11.6 | 10.8 | 6,026 |
| inappropriate schedule of drug administrationSignal | 617 | 8.5 | 7.9 | 4,055 |
| blood glucose increasedSignal | 1,511 | 7.9 | 7.5 | 9,042 |
| acute kidney injurySignal | 838 | 5.4 | 5.0 | 2,965 |
| no adverse eventSignal | 623 | 3.4 | 3.1 | 1,032 |
| weight decreasedSignal | 718 | 2.5 | 2.3 | 655 |
| diarrhoeaSignal | 1,398 | 2.1 | 2.0 | 838 |
| product dose omission issueSignal | 614 | 2.0 | 1.9 | 325 |
| vomiting | 781 | 1.6 | 1.5 | 187 |
| nausea | 1,110 | 1.4 | 1.3 | 112 |
| dizziness | 639 | 1.2 | 1.2 | 32 |
| fatigue | 902 | 1.1 | 1.1 | 13 |
| dyspnoea | 623 | 1.1 | 1.0 | 3 |
| drug ineffective | 1,006 | 0.7 | 0.7 | 96 |
| death | 606 | 0.7 | 0.6 | 92 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.